Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

The Potential Return on Public Investment in Detecting Adverse Drug Effects.

Huybrechts KF, Desai RJ, Park M, Gagne JJ, Najafzadeh M, Avorn J.

Med Care. 2017 Jun;55(6):545-551. doi: 10.1097/MLR.0000000000000717.

PMID:
28505041
2.

Time spent in hospital after liver transplantation: Effects of primary liver disease and comorbidity.

Tovikkai C, Charman SC, Praseedom RK, Gimson AE, van der Meulen J.

World J Transplant. 2016 Dec 24;6(4):743-750. doi: 10.5500/wjt.v6.i4.743.

3.

Societal reintegration following cadaveric orthotopic liver transplantation.

Kelly R, Hurton S, Ayloo S, Cwinn M, De Coutere-Bosse S, Molinari M.

Hepatobiliary Surg Nutr. 2016 Jun;5(3):234-44. doi: 10.21037/hbsn.2016.03.04.

4.

Effect of Transplant Center Volume on Cost and Readmissions in Medicare Lung Transplant Recipients.

Mooney JJ, Weill D, Boyd JH, Nicolls MR, Bhattacharya J, Dhillon GS.

Ann Am Thorac Soc. 2016 Jul;13(7):1034-41. doi: 10.1513/AnnalsATS.201601-017OC.

5.

Reducing transfusion requirements in liver transplantation.

Donohue CI, Mallett SV.

World J Transplant. 2015 Dec 24;5(4):165-82. doi: 10.5500/wjt.v5.i4.165. Review.

6.

Future Economics of Liver Transplantation: A 20-Year Cost Modeling Forecast and the Prospect of Bioengineering Autologous Liver Grafts.

Habka D, Mann D, Landes R, Soto-Gutierrez A.

PLoS One. 2015 Jul 15;10(7):e0131764. doi: 10.1371/journal.pone.0131764. eCollection 2015.

7.

Is liver transplantation safe and effective in elderly (≥70 years) recipients? A case-controlled analysis.

Wilson GC, Quillin RC 3rd, Wima K, Sutton JM, Hoehn RS, Hanseman DJ, Paquette IM, Paterno F, Woodle ES, Abbott DE, Shah SA.

HPB (Oxford). 2014 Dec;16(12):1088-94. doi: 10.1111/hpb.12312. Epub 2014 Aug 6.

8.

Expanded criteria donors.

Feng S, Lai JC.

Clin Liver Dis. 2014 Aug;18(3):633-49. doi: 10.1016/j.cld.2014.05.005. Review.

9.

Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals.

Hagan LM, Sulkowski MS, Schinazi RF.

Hepatology. 2014 Jul;60(1):37-45. doi: 10.1002/hep.27151. Epub 2014 May 14.

10.

Liver transplantation in alcoholic liver disease current status and controversies.

Singal AK, Chaha KS, Rasheed K, Anand BS.

World J Gastroenterol. 2013 Sep 28;19(36):5953-63. doi: 10.3748/wjg.v19.i36.5953. Review.

11.

Solid-organ transplantation in older adults: current status and future research.

Abecassis M, Bridges ND, Clancy CJ, Dew MA, Eldadah B, Englesbe MJ, Flessner MF, Frank JC, Friedewald J, Gill J, Gries C, Halter JB, Hartmann EL, Hazzard WR, Horne FM, Hosenpud J, Jacobson P, Kasiske BL, Lake J, Loomba R, Malani PN, Moore TM, Murray A, Nguyen MH, Powe NR, Reese PP, Reynolds H, Samaniego MD, Schmader KE, Segev DL, Shah AS, Singer LG, Sosa JA, Stewart ZA, Tan JC, Williams WW, Zaas DW, High KP.

Am J Transplant. 2012 Oct;12(10):2608-22. doi: 10.1111/j.1600-6143.2012.04245.x. Epub 2012 Sep 7.

12.

Centre volume and resource consumption in liver transplantation.

Macomber CW, Shaw JJ, Santry H, Saidi RF, Jabbour N, Tseng JF, Bozorgzadeh A, Shah SA.

HPB (Oxford). 2012 Aug;14(8):554-9. doi: 10.1111/j.1477-2574.2012.00503.x. Epub 2012 Jun 10.

13.

Cost-effectiveness and population outcomes of general population screening for hepatitis C.

Coffin PO, Scott JD, Golden MR, Sullivan SD.

Clin Infect Dis. 2012 May;54(9):1259-71. doi: 10.1093/cid/cis011. Epub 2012 Mar 12.

14.

Defining readmission risk factors for liver transplantation recipients.

Shankar N, Marotta P, Wall W, Albasheer M, Hernandez-Alejandro R, Chandok N.

Gastroenterol Hepatol (N Y). 2011 Sep;7(9):585-90.

15.

The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings.

Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW, Patel N, Ward JW, Weinbaum CM.

Ann Intern Med. 2012 Feb 21;156(4):263-70. doi: 10.7326/0003-4819-156-4-201202210-00378. Epub 2011 Nov 4.

16.

The interaction among donor characteristics, severity of liver disease, and the cost of liver transplantation.

Salvalaggio PR, Dzebisashvili N, MacLeod KE, Lentine KL, Gheorghian A, Schnitzler MA, Hohmann S, Segev DL, Gentry SE, Axelrod DA.

Liver Transpl. 2011 Mar;17(3):233-42. doi: 10.1002/lt.22230.

17.

Long-term outcomes and costs of ventricular assist devices among Medicare beneficiaries.

Hernandez AF, Shea AM, Milano CA, Rogers JG, Hammill BG, O'Connor CM, Schulman KA, Peterson ED, Curtis LH.

JAMA. 2008 Nov 26;300(20):2398-406. doi: 10.1001/jama.2008.716.

18.

Societal reintegration after liver transplantation: findings in alcohol-related and non-alcohol-related transplant recipients.

Cowling T, Jennings LW, Goldstein RM, Sanchez EQ, Chinnakotla S, Klintmalm GB, Levy MF.

Ann Surg. 2004 Jan;239(1):93-8.

19.

Left ventricular assist devices as permanent heart failure therapy: the price of progress.

Oz MC, Gelijns AC, Miller L, Wang C, Nickens P, Arons R, Aaronson K, Richenbacher W, van Meter C, Nelson K, Weinberg A, Watson J, Rose EA, Moskowitz AJ.

Ann Surg. 2003 Oct;238(4):577-83; discussion 583-5.

20.

Pretransplant model to predict posttransplant survival in liver transplant patients.

Ghobrial RM, Gornbein J, Steadman R, Danino N, Markmann JF, Holt C, Anselmo D, Amersi F, Chen P, Farmer DG, Han S, Derazo F, Saab S, Goldstein LI, McDiarmid SV, Busuttil RW.

Ann Surg. 2002 Sep;236(3):315-22; discussion 322-3.

Supplemental Content

Support Center